Microsoft word - main issues frequently raised in the office action.doc
Main Issues Frequently Raised in the Office Action
Han Sung International Patent & Law Office
1. Pharmacological Use in the Composition Claim [Art. 42(4) of KPA]
A. Pharmaceutical composition comprising a novel compound
• Use is not required to be defined in a composition claim if the characteristic inventiveness
lies in a novel compound itself in the composition.
• But, in practice, most examiners require applicant to define a pharmacological use in the
composition claim, regardless of whether or not the compound in the composition is novel.
B. Pharmaceutical composition comprising a known compound
• In case characteristic inventiveness does not exist in an active compound nor in other
ingredients of a pharmaceutical composition, use of the composition will be a unique
characteristic of the invention. In the case, the use should be clear to a skilled person, and
so should be defined by the name of disease.
C. Can the pharmacological mechanism be regarded as sufficiently defining the use of
• In principle, it is not regarded as sufficiently defining the use. But, if the mechanism is
clear to a skilled artisan and the scope of protection is regarded as definite, the use of
composition defined by such mechanism, i.e. anti-histamic agent, may be allowed.
D. Pharmacological test data to support the claimed use
• Though the pharmacological mechanism is proved by experimental data in the specification,
the relationship between diseases in the claims and pharmacological mechanism should be
clearly explained in the specification or supported by other reference(s).
2. Allowable Scope of Novel Compound [Art. 42(3) and 42(4) of KPA]
• Characteristic substituents should be supported by exemplified compounds and equivalents
• Conventional substituents need not be restricted, but should be conventionally reasonable.
※ In practice, the carbon number of alkyl or the kinds of aryl are required to be defined
3. Unacceptable Terms in the Claims [Art. 42(4) of KPA]
• Most examiners tend to object to the above terms without considering characteristic of the
invention. Since these terms have little significant effect to the scope of invention, we
usually propose to change the objected terms to other allowable expressions having same
- “optionally substituted” → “unsubstituted or substituted”
- “A and/or B” → “A or B, or A and B” (‘or A and B’ is usually omitted)
• The expression “use of ~” in the claims is not allowable on the ground that “use” is not a
statutory patentable subject matter. We usually propose to change the expression to other
allowable ones having same scope of protection.
- Use of the compound (I) for manufacture of a medicament for treating amnesia
→ An agent for treating amnesia comprising an effective amount of the compound (I)
4. Experimental Data Supporting Claimed Use [Art. 42(3) of KPA]
• Only representative compounds need to be tested for pharmacological activity, and other
compounds having same general formula are assumed to have same or equivalent effect to
the representative compounds unless the Examiner proves otherwise.
• In a novel compound, the scope of compound defined by use may be much broader than
supported by the examples. But, for a known compound whose characteristic
inventiveness lies in a new use thereof, the scope of compound is limited to those for which
the activity is proven, and close equivalents thereof.
• If the safety of compound is doubtful, an Examiner may request an applicant to submit
experimental data showing the safety of the compound. That is, safety (toxicity) data can
be submitted during the examination procedure.
6. Dose and Administration Method [Art. 42(3) of KPA]
• If the dose and administration method of a related compound were known in the art, the
dose and administration method of the claimed compound having similar physico-chemical
7. Non-Quantitative Pharmacological Effect [Art. 42(3) of KPA]
A. General statement such as “the present compounds show a very potent activity in ~”
• If the pharmacological mechanism of the compound has been clearly established in the art,
quantitative experimental data showing the compound’s pharmacological effect may not be
required (e.g.: ‘the present cephalosporin derivatives show a broad antibiotic activity’).
• But, if the claimed compounds are very similar to the known compounds, the examiner
usually requires submitting comparative experimental data of proving higher effect in order
B. Broad statement such as “the present compound has an IC50 from 0.1 nM to 1 µM”
• Such broad statement on the activity of compounds is not regarded as enough to proving
the effect of compounds. At least one example showing exact activity data of a
representative compound should be shown in the originally filed specification.
(3) The detailed explanation of the invention under paragraph (2)(iii) must state the purpose,
construction and effect of the invention in such a manner that it may easily be carried out by a
person with ordinary skill in the art to which the invention pertains.
(4) The claim(s) under paragraph (2)(iv) must describe the matter for which protection is sought in
one or more claims (referred to as "claim(s)"), and the claim(s) must comply with each of the
(i) the claim(s) must be supported by a detailed explanation of the invention;
(ii) the claim(s) must define the invention clearly and concisely; and
(iii) the claim(s) must define only the features indispensable for the construction of the
(5) Details on the drafting of claim(s) under paragraph (2)(iv) are prescribed by the Presidential
The above summary is general information, and cannot be construed as specific answer for a case.
If you have a specific question, please contact:
Han Sung International Patent & Law Office
Mail: Kang Nam P.O. Box 1793 Seoul 135 080 Korea
Pediatr Nephrol (2010) 25:169–172DOI 10.1007/s00467-009-1284-9Cellular stress-response modulators in the acute rat modelof peritoneal dialysisMichael Boehm & Helga Bergmeister &Klaus Kratochwill & Regina Vargha &Hans Lederhuber & Christoph AufrichtReceived: 9 February 2009 / Revised: 25 May 2009 / Accepted: 15 June 2009 / Published online: 25 August 2009# IPNA 2009Abstrac
Trimethoprim-Sulfamethoxazole Revisited Philip A. Masters, MD; Thomas A. O’Bryan, MD; John Zurlo, MD; Debra Q. Miller, MD; Nirmal Joshi, MD D uringthepast3decades,thecombinationoftrimethoprimandsulfamethoxazole has occupied a central role in the treatment of various commonly encountered in-fections and has also been particularly useful for several specific clinical conditions. However, ch